Biotech · Private company · Aurora, CO, US
Neurexis Therapeutics, Inc.
Track this companyFree. Adds Neurexis Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards6
- Restoring AD-related neuronal dysfunction with a neuroprotective peptideFiscal year 2026 · $484.9KNIH RePORTER 1R43AG094353-01A1 · fetched Nov 12, 2026
- IND-enabling studies for a potent and efficient neuroprotective drugFiscal year 2026 · $238.1KNIH RePORTER 5R44NS120427-04 · fetched Nov 12, 2026
- IND-enabling studies for a potent and efficient neuroprotective drugFiscal year 2025 · $1.8MNIH RePORTER 5R44NS120427-03 · fetched Nov 12, 2026
- Comparative testing of tatCN19o for neuroprotection in rodent tMCAoFiscal year 2025 · $299.6KNIH RePORTER 5U44NS132339-03 · fetched Nov 12, 2026
- IND-enabling studies for a potent and efficient neuroprotective drugFiscal year 2024 · $938.2KNIH RePORTER 2R44NS120427-02A1 · fetched Nov 12, 2026
- Comparative testing of tatCN19o for neuroprotection in rodent tMCAoFiscal year 2024 · $299.6KNIH RePORTER 5U44NS132339-02 · fetched Nov 12, 2026